drugset / Trial / NCT00788164

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

NCT00788164

Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from DNA or a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the cervix may be an effective treatment for cervical intraepithelial neoplasia. Giving vaccine therapy together with imiquimod may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy and to see how well it works when given with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia.

Timeline

Start
2008-11
Primary completion
2023-08
Completion
2023-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified Topical
Subject TA-HPV Vaccine Intramuscular
Subject pNGVL4a-SigE7(detox)HSP70 Vaccine Intramuscular